CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Overnight digest: Stocks to watch on June 30
Shreya Chaware
/ Categories: Trending, DSIJ News

Overnight digest: Stocks to watch on June 30

The stocks to watch as of June 30 include ISGEC Heavy Engineering, Kamat Hotels and certain pharma majors like Sun Pharmaceuticals, Cipla, Torrent Pharmaceuticals, Emcure Pharmaceuticals, Dr Reddy's Laboratories along with Finolex Cables & United Drilling Tools. 

ISGEC Heavy Engineering: The company informed that it has received a prestigious order for a wet limestone flue gas desulphurisation system and flue gas conditioning system package (FGD-FGC Package) from Odisha Power Generation Corporation for its 2x660 MW TPPIB Thermal Power Station at Banharpali, Jharsuguda (Odisha).  

Kamat Hotels: The company declared its financial results for Q4FY21. Revenue from operations stood at Rs 22.80 crore in Q4FY21 in comparison with Rs 44.84 crore in Q4FY20, declining by 49.15 per cent. The total income for the quarter also showed a dip of 48.15 per cent as compared to the corresponding quarter in the previous fiscal year. The company incurred a net loss of Rs 488.05 crore in Q4FY21 as against the net profit of Rs 2,132.64 crore in Q4FY20. 

Pharma majors: The Pharma majors such as Sun Pharmaceuticals, Cipla, Torrent Pharmaceuticals, Emcure Pharmaceuticals, and Dr Reddy's Laboratories are collaborating for the clinical trial of the investigational oral anti-viral drug, Molnupiravir for the treatment of mild COVID-19 in an outpatient setting in India. 

Finolex Cables: The board has recommended a final dividend at Rs 5.50 per equity share of Rs 2 each fully paid-up) for the financial year ended March 31, 2021, subject to the approval of shareholders at ensuing annual general meeting of the company. 

United Drilling Tools: The company announced its financial results for the fourth quarter of FY21. Revenue from operations rose by 27.83 per cent on a YoY basis on the back of procurement of big orders of Rs 125 crore from ONGC executed in FY21. EBITDA witnessed a decrease of 23.71 per cent YoY, owing to the increase in raw material consumption cost due to a surge in steel process and non-availability of labour due to COVID-19. Meanwhile, its net profit improved by 26.65 per cent in Q4FY21 on a YoY basis. 

Previous Article What are Gilt funds?
Next Article Five pharma companies to collaborate for clinical trial of Molnupiravir for treating mild COVID-19
Print
2200 Rate this article:
4.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR